Database : MEDLINE
Search on : Dermatofibrosarcoma [Words]
References found : 1861 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 187 go to page                         

  1 / 1861 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29377717
[Au] Autor:Haller J; David MP; Lee NE; Shalin SC; Gardner JM
[Ti] Title:Impact of Pathologist Involvement in Sarcoma and Rare Tumor Patient Support Groups on Facebook: A Survey of 542 Patients and Family Members.
[So] Source:Arch Pathol Lab Med;, 2018 Jan 29.
[Is] ISSN:1543-2165
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:CONTEXT: - Patients with rare tumors have difficulty finding reliable information about their disease. Facebook patient support groups allow patients to educate one another. OBJECTIVE: - To investigate how these patients perceive the value of pathologists, both in Facebook groups and real-world patient care. DESIGN: - Survey links were posted in 12 Facebook patient groups: 6 with an active pathologist member (angiosarcoma, epithelioid hemangioendothelioma, epithelioid sarcoma, dermatofibrosarcoma protuberans [×2], and desmoid fibromatosis), and 6 without "active" pathologist involvement (aggressive angiomyxoma, chondrosarcoma, Ewing sarcoma, leiomyosarcoma, liposarcoma, and osteosarcoma). RESULTS: - A total of 542 people responded (403 were patients): 264 from groups with a pathologist, and 278 from groups without active pathologist involvement. Of groups with an active pathologist, respondents agreed the pathologist's posts helped them better understand their disease (107 of 119; 90%) and relieved some of their disease-related anxiety (92 of 119; 77%). And for these groups 98% (117 of 119) of respondents agreed that having a pathologist in their group was a good thing; 83% (192 of 232) wanted more pathologists involved. More respondents from groups with an active pathologist (219 of 236; 93%) than without one (215 of 252; 85%) agreed: "pathologists are an important part of the patient care team for patients with cancer and other rare tumors" ( P = .008). CONCLUSIONS: - This study is the first to evaluate the impact of pathologist interaction with Facebook patient support groups and to assess perceptions about the specialty of pathology from a large group of patients with rare tumors. Pathologist involvement in Facebook patient groups appears to positively influence patient perception of the importance of pathologists. We hope these data will encourage more pathologists to participate in Facebook patient support groups.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.5858/arpa.2017-0408-OA

  2 / 1861 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29400030
[Au] Autor:Clarós P; Clarós A; Sarr MC
[Ti] Title:[Dermatofibrosarcoma protuberans of the face: Long term patient of a follow up].
[So] Source:Rev Laryngol Otol Rhinol (Bord);136(3):113-5, 2015.
[Is] ISSN:0035-1334
[Cp] Country of publication:France
[La] Language:fre
[Ab] Abstract:We report the case of a patient 40 years old affected by a facial tumour diagnosed as a dermatofibrosarcoma protu­berans. He has been followed in our clinic for the last 22 years. He got a recurrency after 11 years and after an other surgery he his actually free of disease. The purpose of this article is to evaluate the tumoral recurrency and the long term follow up.
[Mh] MeSH terms primary: Dermatofibrosarcoma/pathology
Skin Neoplasms/pathology
[Mh] MeSH terms secundary: Adult
Dermatofibrosarcoma/surgery
Disease-Free Survival
Humans
Male
Neoplasm Recurrence, Local/surgery
Skin Neoplasms/surgery
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[Js] Journal subset:IM
[Da] Date of entry for processing:180206
[St] Status:MEDLINE

  3 / 1861 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29517116
[Au] Autor:Bishnoi A; De D; Parsad D; Saikia UN
[Ad] Address:Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
[Ti] Title:Dermatofibrosarcoma protuberans-A rare lesion on breast.
[So] Source:Breast J;, 2018 Mar 08.
[Is] ISSN:1524-4741
[Cp] Country of publication:United States
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1111/tbj.13016

  4 / 1861 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29516936
[Au] Autor:Kishanprasad HL; Lobo L; Shetty JK; Impana BD
[Ad] Address:Department of Pathology, KS Hegde Medical Academy, Nitte University, Mangalore, Karnataka, India.
[Ti] Title:Giant cells in soft tissue tumors! Is it a clue to diagnosis or cytologists mystery??? An unusual case report.
[So] Source:J Cancer Res Ther;14(2):444-446, 2018 Jan-Mar.
[Is] ISSN:1998-4138
[Cp] Country of publication:India
[La] Language:eng
[Ab] Abstract:Giant cells in soft tissue (ST) tumors are rare, pose great challenges to treating clinicians, and diagnosing pathologists. Common lesion with giant cells includes benign conditions such as nodular fasciitis to highly malignant lesions such as giant cell variant of malignant fibrous histiocytoma and extraskeletal osteosarcoma. Giant cell tumors of ST, extension of bony lesion to the ST are also rare possibilities. Recently, giant cell fibroblastoma and dermatofibrosarcoma protuberans have also been added to this list. These tumors show unpredictable behavior; some patients are cured by simple surgical excision whereas others develop metastasis. Diagnosing these in cytology is still more challenging. We report here a rare case of a giant cell-rich dermatofibrosarcoma protuberans in a 23-year-old male who presented with ST lesion in left forearm since 6 months. The lesion was predicted in fine-needle aspiration cytology and confirmed later with histopathology. When evaluated along with clinical features, the cytological features are very useful to distinguish between these tumors with giant cell morphology.
[Pt] Publication type:LETTER
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Process
[do] DOI:10.4103/0973-1482.199433

  5 / 1861 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29510612
[Au] Autor:Won HS; Chang ED; Na SJ; Whang IY; Lee DS; You SH; Kim YS; Kim JS
[Ad] Address:Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, Korea.
[Ti] Title:PTEN Mutation Identified in Patient Diagnosed with Simultaneous Multiple Cancers.
[So] Source:Cancer Res Treat;, 2018 Feb 27.
[Is] ISSN:2005-9256
[Cp] Country of publication:Korea (South)
[La] Language:eng
[Ab] Abstract:PTEN hamartoma tumor syndrome is a spectrum of disorders characterized by unique phenotypic features including multiple hamartomas caused by mutations of the tumor suppressor gene PTEN. Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome are representative diseases, and both have several common clinical features and differences. Because PTEN mutations are associated with an increased risk of malignancy including breast, thyroid, endometrial, and renal cancers, cancer surveillance is an important element of disease management. We report a germline mutation of the PTEN (c.723dupT, exon 7) identified in a young woman with a simultaneous occurrence of breast cancer, dermatofibrosarcoma protuberans, and follicular neoplasm. This case suggests that it is critical for clinicians to recognize the phenotypic features associated with these syndromes to accurately diagnose them and provide preventive care.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:Publisher
[do] DOI:10.4143/crt.2017.579

  6 / 1861 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29509956
[Au] Autor:Molina AS; Duprat Neto JP; Bertolli E; da Cunha IW; Fregnani JHTG; Figueiredo PHM; Soares FA; Macedo MP; Pinto Lopes CA; de Abranches Oliveira Santos Filho ID
[Ad] Address:Skin Cancer Department, AC Camargo Cancer Hospital, São Paulo, Brazil.
[Ti] Title:Relapse in dermatofibrosarcoma protuberans: A histological and molecular analysis.
[So] Source:J Surg Oncol;, 2018 Mar 06.
[Is] ISSN:1096-9098
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Dermatofibrosarcoma protuberans (DFSP) is a rare low grade tumor with a locally aggressive behavior and low metastatic potential. OBJECTIVES: To evaluate the factors that are associated with relapse in DFSP. Methods Retrospective analysis of medical records from 61 patients with dermatofibrosarcoma. Fluorescence in situ hybridization was used to detect translocations. RESULTS: Of 61 patients, 6 experienced a relapse. No patient with resection margins greater than 3 cm had a recurrence. One relapse was observed in a patient treated with at least 2 cm margins and 4 relapses occurred in 16 patients whose margins were below 2 cm (P = 0.018). The frequency of translocations was 77.8%. The recurrence rate was lower in patients with translocation, but this difference was not significant. Immunohistochemical markers did not correlate with recurrence rates, but greater FasL expression was associated with recurrence in patients with margins smaller than 3 cm. CONCLUSIONS: Surgical margins smaller than than 2 cm are related to higher recurrences in dermatofibrosarcomas. In this analysis a 2 cm margin was acceptable for treatment. Between all the immunohistochemical markers analyzed, only FasL was associated with a higher recurrence rate in patients with margins smaller than 3 cm.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[St] Status:Publisher
[do] DOI:10.1002/jso.25039

  7 / 1861 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29416224
[Au] Autor:Ucak M
[Ad] Address:Plastic and Reconstructive Surgery, Nevsehir Public Hospital, Nevsehir, Turkey.
[Ti] Title:A Rare Case of Misdiagnosis: Recurrence of Dermatofibrosarcoma Protuberans That Was Treated Surgicallyas a Keloid.
[So] Source:Med Arch;72(1):74-75, 2018 Feb.
[Is] ISSN:0350-199X
[Cp] Country of publication:Bosnia and Herzegovina
[La] Language:eng
[Ab] Abstract:Aim: In this report, we presented the patient with Dermatofibrosarcoma Protuberans (DFSP), removed by considering as the keloid scar in the general surgery clinic with misdiagnosis. Case report: The patient was a 19-year-old female student with no scar or previous trauma history in the lesion area. Pathology report of excisional biopsy revealed as a DFSP, reachedsubcutis and dermis. In staging by CT, there had been no distant metastases. There was a lesion with the size of 2x1.5x1.5cm. A large resection was made to include the entire mass and the lower fascia. The defect area was repaired with a Limberg flap. There was no tumor recurrence in the first 6 months following the operation with high-level aesthetics for patient satisfaction. Conclusion: DFSP should be remembered in cases of operative or spontaneous keloid scarring lesions. The surgical treatment is possible after extensive resection with flap or graft repair.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Process
[do] DOI:10.5455/medarh.2018.72.74-75

  8 / 1861 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29318761
[Au] Autor:Song W; van Hemel BM; Suurmeijer AJH
[Ad] Address:Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, RB Groningen, 9700, The Netherlands.
[Ti] Title:Suitability of the Cellient cell block method for diagnosing soft tissue and bone tumors.
[So] Source:Diagn Cytopathol;46(4):299-305, 2018 Apr.
[Is] ISSN:1097-0339
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: The diagnosis of tumors of soft tissue and bone (STB) heavily relies on histological biopsies, whereas cytology is not widely used. Cellient cell blocks often contain small tissue fragments. In addition to Hematoxylin and Eosin (H&E) interpretation of histological features, immunohistochemistry (IHC) can be applied after optimization of protocols. The objective of this retrospective study was to see whether this cytological technique allowed us to make a precise diagnosis of STB tumors. METHODS: Our study cohort consisted of 20 consecutive STB tumors, 9 fine-needle aspiration (FNAC) samples, and 11 endoscopic ultrasonography (EUS) FNACs and included 8 primary tumors and 12 recurrences or metastases of known STB tumors. RESULTS: In all 20 cases, H&E stained sections revealed that diagnostically relevant histological and cytological features could be examined properly. In the group of 8 primary tumors, IHC performed on Cellient material provided clinically important information in all cases. For instance, gastrointestinal stromal tumor (GIST) was positive for CD117 and DOG-1 and a PEComa showed positive IHC for actin, desmin, and HMB-45. In the group of 12 secondary tumors, SATB2 was visualized in metastatic osteosarcoma, whereas expression of S-100 was present in 2 secondary chondrosarcomas. Metastatic chordoma could be confirmed by brachyury expression. Two metastatic alveolar rhabdomyosarcomas were myf4 positive, a metastasis of a gynecologic leiomyosarcoma was positive for actin and estrogen receptor (ER) and a recurrent dermatofibrosarcoma protuberans expressed CD34. CONCLUSION: In the proper clinical context, including clinical presentation with imaging studies, the Cellient cell block technique has great potential for the diagnosis of STB tumors.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Process
[do] DOI:10.1002/dc.23887

  9 / 1861 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29502795
[Au] Autor:Amavi AK; Dossouvi T; Padaro E; Adabra K; Dosseh ED
[Ad] Address:Centre hospitalier universitaire Sylvanus-Olympio, Chirurgie générale-viscérale, Cancérologie chirurgicale, clinique médico-chirurgicale, 08BP 57 Lomé, Togo; Centre hospitalier universitaire Kara, CHU de SO, Service d'anatomie pathologique, Lomé, Togo. Electronic address: k_amavi@hotmail.com.
[Ti] Title:Traitement des dermatofibrosarcomes protubérants localement évolués au Togo. [Management for locally advanced dermatofibrosarcoma protuberans in Togo].
[So] Source:Bull Cancer;, 2018 Mar 01.
[Is] ISSN:1769-6917
[Cp] Country of publication:France
[La] Language:fre
[Pt] Publication type:LETTER
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[St] Status:Publisher

  10 / 1861 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29408302
[Au] Autor:Roskoski R
[Ad] Address:Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC, 28742-8814, United States. Electronic address: rrj@brimr.org.
[Ti] Title:The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders.
[So] Source:Pharmacol Res;129:65-83, 2018 Mar.
[Is] ISSN:1096-1186
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Platelet-derived growth factor (PDGF) was discovered as a serum-derived component necessary for the growth of smooth muscle cells, fibroblasts, and glial cells. The PDGF family is a product of four gene products and consists of five dimeric isoforms: PDGF-AA, PDGF-BB, PDGF-CC, PDGF-DD, and the PDGF-AB heterodimer. This growth factor family plays an essential role in embryonic development and in wound healing in the adult. These growth factors mediate their effects by binding to and activating their receptor protein-tyrosine kinases, which are encoded by two genes: PDGFRA and PDGFRB. The functional receptors consist of the PDGFRα/α and PDGFRß/ß homodimers and the PDGFRα/ß heterodimer. Although PDGF signaling is most closely associated with mesenchymal cells, PDGFs and PDGF receptors are widely expressed in the mammalian central nervous system. The PDGF receptors contain an extracellular domain that is made up of five immunoglobulin-like domains (Ig-d1/2/3/4/5), a transmembrane segment, a juxtamembrane segment, a protein-tyrosine kinase domain that contains an insert of about 100 amino acid residues, and a carboxyterminal tail. Although uncommon, activating mutations in the genes for PDGF or PDGF receptors have been documented in various neoplasms including dermatofibrosarcoma protuberans (DFSP) and gastrointestinal stromal tumors (GIST). In most neoplastic diseases, PDGF expression and action appear to involve the tumor stroma. Moreover, this family is pro-angiogenic. More than ten PDGFRα/ß multikinase antagonists have been approved by the FDA for the treatment of several neoplastic disorders and interstitial pulmonary fibrosis (www.brimr.org/PKI/PKIs.htm). Type I protein kinase inhibitors interact with the active enzyme form with DFG-D of the proximal activation segment directed inward toward the active site (DFG-D ). In contrast, type II inhibitors bind to their target with the DFG-D pointing away from the active site (DFG-D ). We used the Schrödinger induced-fit docking protocol to model the interaction of several antagonists with PDGFRα including imatinib, sorafenib, and sunitinib. The results indicate that these antagonists are able to bind to the DFG-D conformation of the receptor and are thus classified as type II inhibitors. Owing to the multiplicity of less active protein kinase conformations when compared with the canonical more active conformation, it was hypothesized that type II drugs would be less promiscuous than type I drugs which bind to the typical active conformation. Although type II inhibitors may be more selective, most - if not all - inhibit more than one target protein kinase and the differences are a matter of degree only.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180227
[Lr] Last revision date:180227
[St] Status:In-Data-Review


page 1 of 187 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information